The purpose of this study is to evaluate the safety and clinical activity of maintenance olaparib and pembrolizumab following multi-agent, low dose chemotherapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with untreated metastatic pancreatic ductal cancer.
Condition or disease
Metastatic Pancreatic Cancer
Drug: Nab-paclitaxel Drug: Gemcitabine Drug: Cisplatin Drug: Irinotecan Drug: Capecitabine Drug: Pembrolizumab Drug: Olaparib
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.